Researcher Spotlight: Yazeed Sawalha, MD Cleveland Clinic Patients with indolent non-Hodgkin lymphoma who relapse or have refractory lymphoma that does not respond to treatment still have poorer outcomes, with many of the current available treatments having either limited benefit or significant side effects.…
Researcher Spotlight: Allison Rosenthal, DO Mayo Clinic Arizona Mantle cell lymphoma (MCL) can present in a variety of ways, from slow-growing indolent to more aggressive forms with poorer outcomes. Currently a patient’s treatment plan is largely based on patient age…
Researcher Spotlight: Reid Merryman, MD Dana-Farber Cancer Institute Marginal zone lymphoma (MZL) is a slow-growing B-cell NHL that has a relatively low number of new diagnoses each year. As a result, few clinical trials are available for MZL patients, including…
Researcher Spotlight: Rahul Lakhotia, MBBS National Institutes of Health Indolent lymphomas frequently require multiple lines of treatment as the disease recurs; the frequency of treatment makes it important to balance efficacy with potential toxicities (side effects). Dr. Lakhotia’s LCRMP project tests a new…
Researcher Spotlight: Manali Kamdar, MBBS University of Colorado Patients with indolent (slow-growing) lymphomas such as follicular (FL) or marginal zone (MZL) are chronic, frequently relapsing diseases which can vary widely in clinical presentation. Therapies are varied and can often include…
Researcher Spotlight: Andrew Ip, MD Winship Cancer Institute For many lymphoma subtypes, a bone marrow transplant is the recommended treatment strategy following relapse. Previous research has also suggested that lymphoma patients who engage in physical activity during their treatment have better outcomes. However, no…
Researcher Spotlight: Brian Hess, MD Medical University of South Carolina A common treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by an autologous stem cell transplant (a transplant of a patient’s own healthy cells).…
Researcher Spotlight: Raghuveer Ranganathan, MD University of North Carolina, Chapel Hill Though CAR T-cell therapy has been successful for many patients with Non-Hodgkin lymphomas, the nature of the two versions currently approved by the FDA can have some severe side…
Researcher Spotlight: Neha Mehta-Shah, MD Washington University in Saint Louis Peripheral T-cell lymphomas (PTCL) are a rare group of lymphomas that are commonly treated with combination chemotherapy, followed by autologous stem cell transplant for patients with a good response. However,…
Researcher Spotlight: Anita J. Kumar, MD, MSCE Tufts Medical Center For most Hodgkin lymphoma (HL) patients, chemotherapy is the standard treatment. However, patients often have their initial treatment plan modified (through dose adjustment or delays in treatment) due to concerns…
